Botanical Solution announced it has closed another $7.6 million financing, as part of Series A, that will fund the commencement of in-house production of QS-21, pharmaceutical grade vaccine adjuvant. Using cost-effective and scalable proprietary methods, BSI will expand QS-21 use in broader vaccine applications.

Botanical Solution, a Delaware Corporation, has a proprietary platform for sustainable and improved production of consistent, high quality Advanced Botanical Materials (ABM). ABM-01 is the first ABM produced by the company, based on a plant called Quillaja saponaria. ABM-01 is the active ingredient used in two gold standard products, BSI's biopesticide Quillibrium and the vaccine adjuvant QS-21, used in a Shingles blockbuster vaccine, a recently launched RSV vaccine and a Malaria vaccine.